Gina Columbus

Mary Jo Fidler, MD, discusses aiming to improve platinum-based doublet therapy in NSCLC, as well as the role of chemotherapy for non-driver adenocarcinoma in the future.

Grzegorz S. Nowakowski, MD, discusses the ever-changing landscape of mantle cell lymphoma, the intriguing combinations being studied, and the promise that immunotherapy could hold.

Stephen M. Ansell, MD, PhD, discusses the potential of immunotherapy agents in lymphoma, ongoing clinical trials, and where this blends in with chimeric antigen receptor (CAR) T-cell therapy.

Matthew Gubens, MD, discusses how far the field of NSCLC has come with molecular testing, the challenges still ahead, and what novel assays could be on the horizon.

Stephen M. Ansell, MD, PhD, discusses emerging combinations being investigated in patients with mantle cell lymphoma, the possible role of immunotherapy, and challenges oncologists are still struggling with in this population.

Edward B. Garon, MD discusses the challenges researchers are currently facing with immunotherapy in NSCLC and what the future likely holds for the pivotal agents.

Sophie Papa, MD, discusses the early-phase results and the logic behind studying CAR T-cell therapy in solid tumors, such as head and neck cancer.

Lyndsay J. Willmott, MD, highlights the FDA-approved PARP inhibitors for ovarian cancer and how these approvals have impacted clinical practice.

Mike Janicek, MD sheds light on why physicians are slow to educate patients on testing, the detection of genes aside from BRCA1/2, and the lesser-known benefits of getting genetic testing early on in a diagnosis.

Dana Chase, MD, expands on the pivotal clinical trials, managing toxicities, and the questions researchers still need to answer regarding bevacizumab for patients with ovarian cancer.

Frederick L. Locke, MD, discusses the ZUMA-1 trial in non-Hodgkin lymphoma and the next steps going forward.

Heather Dalton, MD, discusses the first-line treatment options currently available for patients with ovarian cancer, pivotal data that have solidified standard approaches, and why chemotherapy will likely always remain critical in the ovarian cancer sphere.

Shana Wingo, MD, explains how surgical approaches have evolved in ovarian cancer.

Clara D. Bloomfield, MD, a groundbreaking researcher in adult leukemia and lymphoma who helped define new roles for women in science, was honored in the Myeloid Neoplasms category with a 2015 Giants of Cancer Care® award, a program that OncLive® developed to recognize leaders in the field.

Leena Gandhi, MD, PhD, discusses emerging developments in the first-line treatment for patients with ALK-positive NSCLC, as well as novel agents emerging in the field.

The PD-1 and CTLA-4 inhibitor combination of nivolumab (Opdivo) and ipilimumab (Yervoy) was associated with a 12% reduction in the risk of death versus nivolumab monotherapy in patients with treatment-naïve advanced melanoma.

Jamie E. Chaft, MD, discusses the effectiveness of osimertinib (Tagrisso) and what the future holds for patients with EGFR-mutant non-small cell lung cancer.

Mark B. Stoopler, MD, discusses ongoing developments in immunotherapy and his vision for the future of non-small cell lung cancer treatment.

Daniel Costin, MD, shares insight on understanding the deeper biology of the immune system, the emerging research with immunotherapy, and the importance of managing associated adverse events.

Daniel B. Costa, MD, PhD, discusses biomarker testing in non-small cell lung cancer and the necessary next steps for PD-L1 testing.

Andre Goy, MD, highlights what researchers can expect next in the field of mantle cell lymphoma, given recent pivotal data from clinical trials.

E. David Crawford, MD, shares insight on incorporating ADT, specifically degarelix, into the prostate cancer landscape and why it remains to be a standard go-to approach for patients.

Thomas F. Gajewski, MD, PhD, discusses how the combination of PD-1 and IDO inhibitors could change the standard of care for patients with melanoma, and highlights other emerging targets on the horizon.

Kiran K. Turaga, MD, discusses advances in surgical approaches for the treatment of patients with melanoma.

Jason J. Luke, MD, discusses adjuvant therapy for patients with melanoma, as well as the future of targeted agents and immunotherapy.

Christopher R. Shea, MD, expresses the importance of expanding melanoma knowledge to more specialists as well as the advancements in pathology over the last several years.

Andrew Kennedy, MD, speaks on the various approaches used in clinical practice to treat patients who have colorectal cancer with liver metastases.

Brian Hemphill, MD, provides insight on some of the challenges currently being faced in gastrointestinal malignancies and how molecular profiles of tumors will dramatically change outcomes for these patients.

Bert O'Neil, MD, discusses the need for novel treatments for patients with metastatic colorectal cancer as well as why researchers need to develop a deeper understanding of tumor biology.

Johanna Bendell, MD, discusses the promising impact of immunotherapy and other emerging agents in the field of gastrointestinal cancer.